BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2 AND Prognosis
30 results:

  • 1. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway.
    Ma Y; Fang Z; Zhang H; Qi Y; Mao Y; Zheng J
    Cell Death Dis; 2024 Apr; 15(3):199. PubMed ID: 38604999
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution.
    Chen D; Wang Q; Dong M; Chen F; Huang A; Chen C; Lu Y; Zhao W; Wang L
    BMC Cancer; 2023 Oct; 23(1):984. PubMed ID: 37845617
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The changes of subtype markers between first and second primary breast cancers.
    Li C; Lyu Z; Wang Z; Hao C; Huang Y; Song F
    Cancer Med; 2023 Jun; 12(12):13649-13660. PubMed ID: 37096879
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Acute heart failure presentation, management, and outcomes in cancer patients: a national longitudinal study.
    Coles B; Welch CA; Motiwale RS; Teece L; Oliver-Williams C; Weston C; de Belder MA; Lambert PC; Rutherford MJ; Paley L; Kadam UT; Lawson CA; Deanfield J; Peake MD; McDonagh T; Sweeting MJ; Adlam D;
    Eur Heart J Acute Cardiovasc Care; 2023 May; 12(5):315-327. PubMed ID: 36888552
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Correlation between molecular prognostic factors and magnetic resonance imaging intravoxel incoherent motion histogram parameters in breast cancer.
    Feng W; Gao Y; Lu XR; Xu YS; Guo ZZ; Lei JQ
    Magn Reson Imaging; 2022 Jan; 85():262-270. PubMed ID: 34740800
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clinicopathological Features of BRCA1/2 Mutation-Positive breast cancer.
    Paik HJ; Jung YJ; Kim DI; Lee S; Jung CS; Kang SK; Kim JJ; Oh SY; Joo JH; Kim HY
    Oncology; 2021; 99(8):499-506. PubMed ID: 34098565
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site.
    Li X; Shao Y; Sheng L; Zhu J; Wang Z; Guo K; Sun L
    Cancer Med; 2021 Feb; 10(3):974-988. PubMed ID: 33405390
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clonality, Antigen Recognition, and Suppression of CD8
    Hammerl D; Massink MPG; Smid M; van Deurzen CHM; Meijers-Heijboer HEJ; Waisfisz Q; Debets R; Martens JWM
    Clin Cancer Res; 2020 Jan; 26(2):505-517. PubMed ID: 31649042
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The reciprocal influences of prognosis between two types of surgical interventions and early breast cancer patients with diverse luminal subtypes: A meta-analysis.
    He L; Zhao S; Liu M; Su Z; Ren Y; Song Y
    Medicine (Baltimore); 2019 Mar; 98(11):e14912. PubMed ID: 30882711
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Therapeutic targeting of HER2-CB
    Blasco-Benito S; Moreno E; Seijo-Vila M; Tundidor I; Andradas C; Caffarel MM; Caro-Villalobos M; Urigüen L; Diez-Alarcia R; Moreno-Bueno G; Hernández L; Manso L; Homar-Ruano P; McCormick PJ; Bibic L; Bernadó-Morales C; Arribas J; Canals M; Casadó V; Canela EI; Guzmán M; Pérez-Gómez E; Sánchez C
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3863-3872. PubMed ID: 30733293
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Appraising MicroRNA-155 as a Noninvasive Diagnostic Biomarker for cancer Detection: A Meta-Analysis.
    Hou Y; Wang J; Wang X; Shi S; Wang W; Chen Z
    Medicine (Baltimore); 2016 Jan; 95(2):e2450. PubMed ID: 26765436
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Prognostic significance of HOXD13 expression in human breast cancer.
    Zhong ZB; Shan M; Qian C; Liu T; Shi QY; Wang J; Liu Y; Liu Y; Huang YX; Pang D
    Int J Clin Exp Pathol; 2015; 8(9):11407-13. PubMed ID: 26617867
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer.
    Hong J; Mao Y; Chen X; Zhu L; He J; Chen W; Li Y; Lin L; Fei X; Shen K
    Tumour Biol; 2016 Mar; 37(3):4135-42. PubMed ID: 26490984
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The E3 ubiquitin ligase cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
    Zhang L; Teng Y; Fan Y; Wang Y; Li W; Shi J; Ma Y; Li C; Shi X; Qu X; Liu Y
    Oncotarget; 2015 Sep; 6(26):22918-33. PubMed ID: 26087197
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial.
    Fontein DBY; Klinten Grand M; Nortier JWR; Seynaeve C; Meershoek-Klein Kranenbarg E; Dirix LY; van de Velde CJH; Putter H
    Ann Oncol; 2015 Jun; 26(6):1254-1262. PubMed ID: 25862439
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A patient-centered methodology that improves the accuracy of prognostic predictions in cancer.
    Kashani-Sabet M; Sagebiel RW; Joensuu H; Miller JR
    PLoS One; 2013; 8(2):e56435. PubMed ID: 23460802
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Clinicopathologic characteristics and prognosis in young Chinese women with breast cancer].
    Liu X; Liu QF; Xu Y; Ouyang T; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
    Zhonghua Yi Xue Za Zhi; 2011 Jul; 91(26):1817-20. PubMed ID: 22093781
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.
    Yi M; Buchholz TA; Meric-Bernstam F; Bedrosian I; Hwang RF; Ross MI; Kuerer HM; Luo S; Gonzalez-Angulo AM; Buzdar AU; Symmans WF; Feig BW; Lucci A; Huang EH; Hunt KK
    Ann Surg; 2011 Mar; 253(3):572-9. PubMed ID: 21209588
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
    Raja SM; Clubb RJ; Bhattacharyya M; Dimri M; Cheng H; Pan W; Ortega-Cava C; Lakku-Reddi A; Naramura M; Band V; Band H
    Cancer Biol Ther; 2008 Oct; 7(10):1630-40. PubMed ID: 18769124
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.